Reference data : LOINC code

Filter


Clear filter

Results
108,248 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType <span class='defaultText'>DefinitionDescription</span> dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
101144-4 Ustekinumab & Ustekinumab Ab panel - Ser/Plas Pt - &nbsp; &nbsp; ACTIVE Ustekinumab and Ustekinumab Ab panel - Serum or Plasma &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PANEL.DRUG/TOX &nbsp; 101144-4 &nbsp; &nbsp; &nbsp; &nbsp; Order &nbsp; &nbsp; &nbsp; 0 USTEK panel SerPl &nbsp; &nbsp; &nbsp; N &nbsp; DRUG/TOXICOLOGY; Drugs; Pan; PANEL.DRUG & TOXICOLOGY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; STELARA�®; USTEK panel 2.75 2.74 &nbsp; Panel &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101145-1 Ustekinumab^trough MCnc Ser/Plas Pt Qn IA &nbsp; ACTIVE Ustekinumab [Mass/volume] in Serum or Plasma by Immunoassay --trough &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mcg/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101145-1 &nbsp; IA &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Ustekinumab Trough SerPl IA-mCnc &nbsp; &nbsp; &nbsp; N &nbsp; DRUG/TOXICOLOGY; Drugs; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; Level; Mass concentration; MEIA; Pl; Plasma; Plsm; Point in time; Pre; Predose; Pre-dose; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; STELARA�®; SUDS 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
101146-9 Monocyte subsets panel - Bld Pt - Flow cytometry &nbsp; ACTIVE Monocyte subsets panel - Blood by Flow cytometry (FC) &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PANEL.CELLMARK &nbsp; 101146-9 &nbsp; Flow cytometry &nbsp; &nbsp; Order &nbsp; &nbsp; &nbsp; 0 Monocyte subsets panel Bld FC &nbsp; &nbsp; &nbsp; N &nbsp; Blood; CELL MARKERS; Dynamic; FC; Pan; PANEL.CELLMARK; Panl; Pnl; Point in time; Random; WB; Whole blood 2.75 2.74 &nbsp; Panel &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101147-7 Monocytes/Leukocytes NFr Bld Pt Qn Flow cytometry &nbsp; ACTIVE Monocytes/Leukocytes in Blood by Flow cytometry (FC) &nbsp; NAM DefinitionDescription &nbsp; &nbsp; % &nbsp; &nbsp; 1.0-6.6% &nbsp; &nbsp; &nbsp; CELLMARK &nbsp; 101147-7 &nbsp; Flow cytometry &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Monocytes NFr Bld FC &nbsp; &nbsp; &nbsp; N &nbsp; Blood; CELL MARKERS; Dynamic; FC; Leuc; Leuk; Leukocyte; Lkcs; Mono; Monocyte; Monos; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; WBC; WBCs; White blood cell; White blood cells; Whole blood 2.79 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; % &nbsp; &nbsp; Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; 0
101148-5 Monocytes.CD14+CD16-/Monocytes NFr Bld Pt Qn &nbsp; &nbsp; ACTIVE CD14+CD16- (Classical) Monocytes/Monocytes in Blood &nbsp; NAM DefinitionDescription &nbsp; &nbsp; % &nbsp; &nbsp; <94.0 % &nbsp; &nbsp; &nbsp; CELLMARK &nbsp; 101148-5 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 MO1/Monocytes NFr Bld &nbsp; &nbsp; &nbsp; N &nbsp; Blood; CD14 Monocytes; CELL MARKERS; FCGR3A; Leu11; Leu-11; Leu11b; Leu-11B; LeuM3; Leu-M3; LPS receptor; LPS-R; MO1; Mo2; Mo-2; Mono; Monocyte; Monos; My4; My-4; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood 2.79 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; % &nbsp; &nbsp; Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; 0
101149-3 Borrelia burgdorferi Ab.IgM index ACnc Ser+CSF Pt Qn &nbsp; &nbsp; ACTIVE Borrelia burgdorferi IgM Ab index [Units/volume] in Serum and CSF &nbsp; MIN DefinitionDescription &nbsp; &nbsp; index value &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 101149-3 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 B burgdor IgM Index Ser+CSF-aCnc &nbsp; &nbsp; &nbsp; N &nbsp; ABS; Aby; AI; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B burg; B burgdor; B burgdorferi; Bb; Both serum and cerebrospinal fluid; Burgdorf; Cerebral spinal fluid; Cerebrospinal Fl; Immune globulin M; Immunoglobulin M; Lyme; Lyme disease; Lymes; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; SR 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; {Index_val} &nbsp; &nbsp; &nbsp; 0
10115-4 ST wave displacement.end.lead V4 Elpot Heart Pt Qn EKG &nbsp; ACTIVE ST wave end displacement in lead V4 &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mV &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; EKG.MEAS &nbsp; 10115-4 &nbsp; EKG &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 ST wave ED L-V4 &nbsp; &nbsp; &nbsp; Y &nbsp; Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Eklund; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; ST wave ED L-V4; Voltage 2.48 1.0i &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mV &nbsp; &nbsp; &nbsp; 0
101150-1 Cardiac output VRat Heart.ventricle.right Pt Qn Fick &nbsp; ACTIVE Right ventricular Cardiac output by Fick method &nbsp; ADD DefinitionDescription &nbsp; &nbsp; L/min &nbsp; &nbsp; where: CO = cardiac output VO2 = oxygen consumption AVDO2 = arteriovenous difference &nbsp; &nbsp; &nbsp; HEMODYN.MOLEC &nbsp; 101150-1 &nbsp; Fick &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 RV Output Fick &nbsp; &nbsp; &nbsp; N &nbsp; Cardiac; CO; Flow; Hemodynamics; HEMODYNAMICS.MOLEC; Hrt; Hrt ventr; Point in time; QNT; Quan; Quant; Quantitative; R; Random; RT; RV; Ventricular; Volume rate; vRate 2.74 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; L/min &nbsp; &nbsp; &nbsp; 0
101151-9 Cardiac output VRat Heart.ventricle.right Pt Qn Indicator dilution &nbsp; ACTIVE Right ventricular Cardiac output by Indicator dilution &nbsp; ADD DefinitionDescription &nbsp; &nbsp; L/min &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; HEMODYN.MOLEC &nbsp; 101151-9 &nbsp; Indicator dilution &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 RV Output Indicator dilution &nbsp; &nbsp; &nbsp; N &nbsp; Cardiac; CO; Dil; Dilut; Flow; Hemodynamics; HEMODYNAMICS.MOLEC; Hrt; Hrt ventr; Point in time; QNT; Quan; Quant; Quantitative; R; Random; RT; RV; Ventricular; Volume rate; vRate 2.74 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; L/min &nbsp; &nbsp; &nbsp; 0
101152-7 Mitochondria whole genome analysis Find Bld/Tiss Pt Doc Molgen &nbsp; ACTIVE Mitochondria whole genome analysis in Blood or Tissue by Molecular genetics method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MOLPATH &nbsp; 101152-7 &nbsp; Molgen &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Mitochondria whole genome analysis Bld/T &nbsp; &nbsp; &nbsp; N &nbsp; Blood; Document; Finding; Findings; Mito; Mitochon; Mitochond; Mitochondrial; Molecular genetics; Molecular pathology; MOLPATH; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101153-5 Chemokine (C-C motif) ligand 14 MCnc Urine Pt Qn IA &nbsp; ACTIVE Chemokine (C-C motif) ligand 14 [Mass/volume] in Urine by Immunoassay &nbsp; MIN DefinitionDescription &nbsp; &nbsp; pg/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CHEM &nbsp; 101153-5 &nbsp; IA &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 CCL14 Ur IA-mCnc &nbsp; &nbsp; &nbsp; N &nbsp; CCL14; Chemistry; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; Level; Mass concentration; MEIA; Point in time; QNT; Quan; Quant; Quantitative; Random; SUDS; UA; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; pg/mL &nbsp; &nbsp; &nbsp; 0
101154-3 Calprotectin MCnc Ser/Plas Pt Qn &nbsp; &nbsp; ACTIVE Calprotectin [Mass/volume] in Serum or Plasma &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mg/L &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CHEM &nbsp; 101154-3 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Calprotectin SerPl-mCnc &nbsp; &nbsp; &nbsp; N &nbsp; Chemistry; Inflammatory Bowel Disease; Level; Mass concentration; MRP8/14; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Rheumatoid arthritis; S100A8/A9; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mg/L &nbsp; &nbsp; &nbsp; 0
101155-0 Alpha hydroxyetizolam/Creatinine MRto Urine Pt Qn Confirm &nbsp; ACTIVE Alpha hydroxyetizolam/Creatinine [Mass Ratio] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mg creatinine &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101155-0 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 A-OH-etizolam/Creat Ur Cfm &nbsp; &nbsp; &nbsp; N &nbsp; Alfa; A-OH-etizolam; A-OH-etizolam/Creatinine; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mg{creat} &nbsp; &nbsp; &nbsp; 0
101156-8 Alpha hydroxyetizolam PrThr Urine Pt Ord Confirm &nbsp; ACTIVE Alpha hydroxyetizolam [Presence] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101156-8 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 A-OH-etizolam Ur Ql Cfm &nbsp; &nbsp; &nbsp; N &nbsp; Alfa; A-OH-etizolam; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101157-6 Flualprazolam/Creatinine MRto Urine Pt Qn Confirm &nbsp; ACTIVE Flualprazolam/Creatinine [Mass Ratio] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mg creatinine &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101157-6 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Flualprazolam/Creat Ur Cfm &nbsp; &nbsp; &nbsp; N &nbsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; flualprazolam; FWF5L8D2BE; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UNII-FWF5L8D2BE; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mg{creat} &nbsp; &nbsp; &nbsp; 0
101158-4 Flualprazolam PrThr Urine Pt Ord Confirm &nbsp; ACTIVE Flualprazolam [Presence] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101158-4 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Flualprazolam Ur Ql Cfm &nbsp; &nbsp; &nbsp; N &nbsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; flualprazolam; FWF5L8D2BE; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UNII-FWF5L8D2BE; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; 0
101159-2 Flubromazolam/Creatinine MRto Urine Pt Qn Confirm &nbsp; ACTIVE Flubromazolam/Creatinine [Mass Ratio] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mg creatinine &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101159-2 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Flubromazolam/Creat Ur Cfm &nbsp; &nbsp; &nbsp; N &nbsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; flubromazolam; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mg{creat} &nbsp; &nbsp; &nbsp; 0
10116-2 ST wave displacement.end.lead V5 Elpot Heart Pt Qn EKG &nbsp; ACTIVE ST wave end displacement in lead V5 &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mV &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; EKG.MEAS &nbsp; 10116-2 &nbsp; EKG &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 ST wave ED L-V5 &nbsp; &nbsp; &nbsp; Y &nbsp; Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Eklund; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; ST wave ED L-V5; Voltage 2.48 1.0i &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mV &nbsp; &nbsp; &nbsp; 0
101160-0 Flubromazolam PrThr Urine Pt Ord Confirm &nbsp; ACTIVE Flubromazolam [Presence] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101160-0 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Flubromazolam Ur Ql Cfm &nbsp; &nbsp; &nbsp; N &nbsp; Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; flubromazolam; GCMS; Illicit; LC/MS/MS; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101161-8 4-Fluorofentanyl/Creatinine MRto Urine Pt Qn Confirm &nbsp; ACTIVE p-Fluorofentanyl/Creatinine [Mass Ratio] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mg creatinine &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101161-8 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 4-Fluorofentanyl/Creat Ur Cfm &nbsp; &nbsp; &nbsp; N &nbsp; 4-Fluorofentanyl; C22H27FN2O; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide; parafluorofentanyl; p-Fluorofentanyl; Point in time; QNT; Quan; Quant; Quantitative; Random; Synthetic opioid; UA; UCr; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; 0
101162-6 4-Fluorofentanyl PrThr Urine Pt Ord Confirm &nbsp; ACTIVE p-Fluorofentanyl [Presence] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101162-6 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 4-Fluorofentanyl Ur Ql Cfm &nbsp; &nbsp; &nbsp; N &nbsp; 4-Fluorofentanyl; Addiction; C22H27FN2O; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide; Ordinal; parafluorofentanyl; p-Fluorofentanyl; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; Synthetic opioid; UA; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101163-4 Brorphine MCnc Urine Pt Qn Confirm &nbsp; ACTIVE Brorphine [Mass/volume] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101163-4 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Brorphine Ur Cfm-mCnc &nbsp; &nbsp; &nbsp; N &nbsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; 0
101164-2 Brorphine/Creatinine MRto Urine Pt Qn Confirm &nbsp; ACTIVE Brorphine/Creatinine [Mass Ratio] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mg creatinine &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101164-2 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Brorphine/Creat Ur Cfm &nbsp; &nbsp; &nbsp; N &nbsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mg{creat} &nbsp; &nbsp; &nbsp; 0
101165-9 Brorphine PrThr Urine Pt Ord Confirm &nbsp; ACTIVE Brorphine [Presence] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101165-9 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Brorphine Ur Ql Cfm &nbsp; &nbsp; &nbsp; N &nbsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; 0
101166-7 Metonitazene MCnc Urine Pt Qn Confirm &nbsp; ACTIVE Metonitazene [Mass/volume] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101166-7 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Metonitazene Ur Cfm-mCnc &nbsp; &nbsp; &nbsp; N &nbsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; 0
108,248 results found